Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.

Ludwig H, Milosavljevic D, Berlanga O, Zojer N, Hübl W, Fritz V, Harding S.

Am J Hematol. 2016 Mar;91(3):295-301. doi: 10.1002/ajh.24268.

2.

IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.

Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X.

Cancer. 2014 Dec 15;120(24):3952-7. doi: 10.1002/cncr.28946. Epub 2014 Aug 12. Erratum in: Cancer. 2015 Mar 1;121(5):800.

3.

Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.

Tovar N, Fernández de Larrea C, Elena M, Cibeira MT, Aróstegui JI, Rosiñol L, Filella X, Yagüe J, Bladé J.

Biol Blood Marrow Transplant. 2012 Jul;18(7):1076-9. doi: 10.1016/j.bbmt.2012.03.004. Epub 2012 Mar 16.

5.

Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.

Magnano L, Fernández de Larrea C, Elena M, Cibeira MT, Tovar N, Aróstegui JI, Pedrosa F, Rosiñol L, Filella X, Yagüe J, Bladé J.

Clin Lymphoma Myeloma Leuk. 2016 Jun;16(6):e71-7. doi: 10.1016/j.clml.2016.02.034. Epub 2016 Feb 27.

PMID:
27013181
6.

Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H.

Leukemia. 2013 Jan;27(1):202-7. doi: 10.1038/leu.2012.159. Epub 2012 Jun 13.

7.

Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.

Batinić J, Perić Z, Šegulja D, Last J, Prijić S, Dubravčić K, Volarić L, Sertić D, Radman I, Bašić-Kinda S, Matišić D, Batinić D, Labar B, Nemet D.

Croat Med J. 2015 Jun;56(3):263-71.

8.

[Assessment of Heavy/ Light Chain Pairs of Immunoglobulin (Hevylite assay) -  Benefit for Stratification of Multiple Myeloma?].

Ščudla V, Lochaman P, Pika T, Zapletalová J, Minařík J, Bačovský J.

Klin Onkol. 2015;28(5):359-69. Czech.

PMID:
26480864
9.

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, Harding SJ.

Leukemia. 2013 Jan;27(1):213-9. doi: 10.1038/leu.2012.197. Epub 2012 Jul 17. Erratum in: Leukemia. 2013 Apr;27(4):996.

10.

Relationship of differences in immunoglobulin heavy/light chain pairs (Hevylite), selected laboratory parameters and stratification systems in different immunochemical types of multiple myeloma.

Scudla V, Lochman P, Pika T, Minarik J, Zapletalova J, Bacovsky J.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Mar;160(1):84-93. doi: 10.5507/bp.2015.032. Epub 2015 Aug 4.

11.

Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.

Beaumont-Epinette MP, Moreau C, Besnard S, Latute F, Collet N, Sebillot M, Grosbois B, Bendavid C, Guenet L, Decaux O.

Pathol Biol (Paris). 2015 Sep;63(4-5):215-21. doi: 10.1016/j.patbio.2015.06.001. Epub 2015 Aug 28.

PMID:
26319969
12.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, Benson JT, Colby CL, Dispenzieri A, Landgren O, Kumar S, Bradwell AR, Cerhan JR, Rajkumar SV.

Leukemia. 2013 Jan;27(1):208-12. doi: 10.1038/leu.2012.189. Epub 2012 Jul 11.

13.

Abnormal heavy/light chain ratio after treatment is associated with shorter survival in patients with IgA myeloma.

Suehara Y, Takamatsu H, Fukumoto K, Fujisawa M, Narita K, Usui Y, Takeuchi M, Endean K, Matsue K.

Cancer Sci. 2017 Feb;108(2):187-192. doi: 10.1111/cas.13125.

14.

Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays.

Katzmann JA, Willrich MA, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR, Rajkumar SV, Dispenzieri A.

Clin Chem. 2015 Feb;61(2):360-7. doi: 10.1373/clinchem.2014.231985. Epub 2014 Dec 1.

15.

Analytical performance and diagnostic potential of immunoassays determining intact immunoglobulin kappa/lambda ratios in monoclonal gammopathies.

Eckold J, Poenisch W, Drogies T, Kratzsch J, Teupser D, Thiery J, Bruegel M.

Clin Lab. 2014;60(9):1491-500.

PMID:
25291945
16.
17.

Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.

Harutyunyan NM, Vardanyan S, Ghermezi M, Gottlieb J, Berenson A, Andreu-Vieyra C, Berenson JR.

Br J Haematol. 2016 Jul;174(1):81-7. doi: 10.1111/bjh.14026. Epub 2016 Mar 27.

PMID:
27017948
18.

Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.

García de Veas Silva JL, Bermudo Guitarte C, Menéndez Valladares P, Rojas Noboa JC, Kestler K, Duro Millán R.

PLoS One. 2016 Nov 28;11(11):e0166841. doi: 10.1371/journal.pone.0166841. eCollection 2016.

19.

Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.

Mori S, Crawford BS, Roddy JV, Phillips G, Elder P, Hofmeister CC, Efebera Y, Benson DM Jr.

Hematol Oncol. 2012 Sep;30(3):156-62. doi: 10.1002/hon.1019. Epub 2011 Oct 26.

Supplemental Content

Support Center